Brief: Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics

04/09/2024 12:34

Sept 4 (Reuters) - Axsome Therapeutics Inc  AXSM.O :
    * AXSOME THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NDA
RESUBMISSION
FOR AXS-07 FOR THE ACUTE TREATMENT OF MIGRAINE
    * AXSOME THERAPEUTICS INC - SET A PRESCRIPTION DRUG USER FEE
ACT
(PDUFA) ACTION GOAL DATE OF JANUARY 31, 2025
    * AXSOME THERAPEUTICS INC - FDA DESIGNATED RESUBMISSION AS A
CLASS
2 RESUBMISSION AND SET A PDUFA ACTION GOAL DATE OF JANUARY 31,
2025

Source text for Eikon:  ID:nGNX7nVtGg 
Further company coverage:  AXSM.O 

 ((Reuters.Briefs@thomsonreuters.com;))